dc.contributor
Institut Català de la Salut
dc.contributor
[Ortiz DA, Peregrín N] DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. [Valencia M] Biomedical Engineering Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. Institute of Data Science and Artifcial Intelligence (DATAI), University of Navarra, Pamplona, Spain. Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [Vinueza Gavilanes R, Ferrero R] DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [Marín Ordovas E] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Ortiz, Didio Alberto
dc.contributor.author
Peregrín, Nuria
dc.contributor.author
Valencia, Miguel
dc.contributor.author
Vinueza-Gavilanes, Rodrigo
dc.contributor.author
Marin-Ordovas, Elisa
dc.contributor.author
Ferrero, Roberto
dc.date.accessioned
2025-10-24T08:52:08Z
dc.date.available
2025-10-24T08:52:08Z
dc.date.issued
2025-01-22T11:42:11Z
dc.date.issued
2025-01-22T11:42:11Z
dc.date.issued
2024-09-20
dc.identifier
Ortiz DA, Peregrín N, Valencia M, Vinueza-Gavilanes R, Marín-Ordovas E, Ferrero R, et al. GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model. Transl Neurodegener. 2024 Sep 20;13:49.
dc.identifier
https://hdl.handle.net/11351/12459
dc.identifier
10.1186/s40035-024-00441-w
dc.identifier
001317459900001
dc.identifier.uri
http://hdl.handle.net/11351/12459
dc.description.abstract
Toxicity; Mouse model; Amyotrophic lateral sclerosis
dc.description.abstract
Toxicidad; Modelo de ratón; Esclerosis lateral amiotrófica
dc.description.abstract
Toxicitat; Model de ratolí; Esclerosi lateral amiotròfica
dc.description.abstract
This work was supported by PID2020‑120497RB‑I00 MCIU/AEI/https://doi.org/ 10.13039/501100011033, BFU2017‑90043‑P MCINN/AEI/https://doi.org/10. 13039/501100011033/ and by FEDER “Una manera de hacer Europa” (MA and TA), Proyecto Intramural IdisNa 2022 (MA), Fundación para la Investigación Médica Aplicada (FIMA) Proyectos I + D, 2017 (TA) and Fundación Occident and DalecandELA Association (MA). DO was supported by República de Panamá, Programa de Becas IFARHU‑SENACYT (reference number 270‑2018‑922), and NP by AC FIMA pre‑doctoral fellowship.
dc.format
application/pdf
dc.relation
Translational Neurodegeneration;13
dc.relation
https://doi.org/10.1186/s40035-024-00441-w
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi lateral amiotròfica - Tractament
dc.subject
Esclerosi lateral amiotròfica - Aspectes genètics
dc.subject
Anomalies cromosòmiques
dc.subject
Proteïnes quinases - Inhibidors - Ús terapèutic
dc.subject
Rates (Animals de laboratori)
dc.subject
DISEASES::Nervous System Diseases::Central Nervous System Diseases::Spinal Cord Diseases::Amyotrophic Lateral Sclerosis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation
dc.subject
CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases
dc.subject
Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors
dc.subject
DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression
dc.subject
ORGANISMS::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Eutheria::Rodentia::Muridae::Murinae::Mice
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades de la médula espinal::esclerosis lateral amiotrófica
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-serina-treonina cinasas
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores
dc.subject
ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad
dc.subject
ORGANISMOS::Eukaryota::animales::Chordata::vertebrados::mamíferos::Eutheria::Rodentia::Muridae::Murinae::ratas
dc.title
GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
